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Abstract
Background: Clinicians are less likely to prescribe guideline-recommended treatments to people with
multimorbidity than to people with a single condition. Doubts as to the applicability of clinical trials of drug
treatments (the gold standard for evidence-based medicine) when people have co-existing diseases (comorbidity)
may underlie this apparent reluctance. Therefore, for a range of index conditions, we measured the comorbidity
among participants in clinical trials of novel drug therapies and compared this to the comorbidity among patients
in the community.
Methods: Data from industry-sponsored phase 3/4 multicentre trials of novel drug therapies for chronic medical
conditions were identified from two repositories: Clinical Study Data Request and the Yale University Open Data
Access project. We identified 116 trials (n = 122,969 participants) for 22 index conditions. Community patients were
identified from a nationally representative sample of 2.3 million patients in Wales, UK. Twenty-one comorbidities
were identified from medication use based on pre-specified definitions. We assessed the prevalence of each
comorbidity and the total number of comorbidities (level of multimorbidity), for each trial and in community
patients.
Results: In the trials, the commonest comorbidities in order of declining prevalence were chronic pain,
cardiovascular disease, arthritis, affective disorders, acid-related disorders, asthma/COPD and diabetes. These
conditions were also common in community-based patients.
Mean comorbidity count for trial participants was approximately half that seen in community-based patients.
Nonetheless, a substantial proportion of trial participants had a high degree of multimorbidity. For example, in
asthma and psoriasis trials, 10–15% of participants had ≥ 3 conditions overall, while in osteoporosis and chronic
obstructive pulmonary disease trials 40–60% of participants had ≥ 3 conditions overall.
Conclusions: Comorbidity and multimorbidity are less common in trials than in community populations with the
same index condition. Comorbidity and multimorbidity are, nevertheless, common in trials. This suggests that
standard, industry-funded clinical trials are an underused resource for investigating treatment effects in people with
comorbidity and multimorbidity.
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Background
Drug treatments that have been recommended in
evidence-based clinical guidelines are less likely to be
prescribed to people with multimorbidity (defined as
people with two or more conditions) [1–5]. One reason
for this difference in prescribing is that the populations
included in clinical trials, which underpin evidence-
based guidelines, are believed to be unrepresentative of
people with multimorbidity [6, 7].
Comorbidity (the presence of other conditions in
addition to a specified index condition) [8] may influ-
ence the effectiveness of treatments for specific condi-
tions through competing risks, drug-drug, drug-disease
and disease-disease interactions, altering the balance of
risks and benefits [9–11]. Underrepresentation of people
with multimorbidity in clinical trials is therefore
concerning.
However, most studies examining clinical trial rep-
resentativeness have done so by analysing routine
clinical practice data (e.g. from disease registers and
electronic health records) to which trial eligibility cri-
teria have been applied [12–17]. Since factors other
than eligibility criteria are likely to influence which
people are recruited to clinical trials [18], such ap-
proaches provide only indirect evidence about the
prevalence of comorbidity and multimorbidity in trial
participants.
We examined the prevalence of comorbidity and mul-
timorbidity among 122,969 participants from 116
industry-funded trials of novel drug therapies for 22
index conditions and compared these results with co-
morbidity and multimorbidity prevalence in 2.3 million
patients living in the community.
Methods
Study design
This cross-sectional analysis compares the distribution
of comorbidity and multimorbidity in participants en-
rolled in 116 industry-sponsored trials and a representa-
tive community sample from the UK. All analyses were
pre-specified (Additional file 1).
Data sources and participants
Trials
We accessed individual-level participant data (IPD)
from industry-sponsored trials from two repositories:
the Clinical Study Data Request (CSDR) and the Yale
University Open Data Access (YODA) project (on 21
November 2016 and 18 May 2018, respectively). From
this set, trials were selected according to a pre-
specified protocol (Prospero CRD42018048202) [19].
Briefly, eligible trials were registered with the US
Clinical Trials register (clincialtrials.gov), had a start
date on or after 1 January 1990 (based on scoping
showing that trials where IPD was available had
started on or after this date), were phase 2/3, 3 or 4,
recruited ≥ 300 participants, had an upper age limit ≥
60 years (or no maximum) and evaluated drugs for a
selected set of chronic conditions (Fig. 1). Conditions
were chosen on the basis that they require long-term
pharmacological therapy. We selected a range of cardio-
vascular, respiratory, gastrointestinal, musculoskeletal,
metabolic, autoimmune and connective tissue, and uro-
logical and otolaryngological disorders. A full list of eli-
gible conditions is shown in Additional file 1: Table S1.8.
Trials for neoplastic, infectious, affective, psychotic or
developmental disorders were excluded, as were trials of
primary prevention in general populations without an
index condition (see Additional file 1). Only randomised
participants were included in analyses. We also searched
the National Institutes of Health (NIH) Biologic Specimen
and Data Repository Information Coordinating Center
(BioLINCC) repository in August 2017, but no trials from
this source were eligible because of lack of reported data
on comorbidities.
Community sample
A community sample was identified using the Secure
Anonymised Information Linkage (SAIL) Databank,
which is a repository of health and administrative data
covering 70% of Wales’s population of three million
[20]. This sample is nationally representative in terms of
age, sex and socioeconomic status (Additional file 2).
We included people registered with a participating pri-
mary care practice between 1 January 2011 and 1 Janu-
ary 2012 (2,289,583 people). This time period was
chosen after accessing the primary care data, prior to
further analysis, as coding of prescribing data was most
complete from this point onwards.
Index conditions
For trial data, index conditions were defined by the
treatment indication, described in the trial registration.
Trials were then grouped by index condition.
For the community sample, we used codes from the
Read classification system to identify people with each
index condition. Read codes are a coding scheme used in
UK primary care electronic health records [21]. The index
condition definitions were adapted from published literature
and from definitions used in the Quality & Outcomes
Framework, a pay-for-performance programme which has
incentivised coding for common chronic conditions
(Additional file 3) [1, 22, 23]. For defining asthma, hyperten-
sion, type 2 diabetes, migraine and thromboembolic disease,
prescribed medications were also used, alongside diagnostic
codes, to confirm that conditions were receiving active
pharmacological treatment [1].
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Fig. 1 a Initial identification of individual-level participant data trials from trial repositories. See Additional file 1 for a detailed description of the
selection process. Abbreviations are as follows: MeSH, Medical Subject Headings; WHO-ATC, World Health Organization Anatomic Therapeutic
Chemical classification scheme; CSDR, Clinical Study Data Request repository; YODA, Yale Open Data Access repository; NIH, National Institutes of
Health Biologic Specimen and Data Repository Information Coordinating Center repository; and IPD, individual-level participant data. b Definition
of “denominator trials” using the US clinical trials registry (clinicaltrials.gov) and the effect of restricting the individual-level participant data trials to
this denominator set. The height of each box on the horizontal axis corresponds to the simultaneous effect of applying the eligibility criteria to
the denominator set of trials (the leftmost chart) and the three numerator sets of IPD trials. For brevity, the leftmost flowchart shows both the
eligibility criteria and the trial counts whereas the other three flowcharts show only the trial counts. Of the final set of 124 trials, further 8 trials
were excluded either because the index condition was either difficult or impossible to accurately identify within the primary care record or
because we judged that concomitant medication may be difficult to interpret in the context of the index condition (see Additional file 1, section
1.7 for details)
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Quantifying comorbidities
Medical history data was frequently redacted in the trial
datasets to maintain patient confidentiality, and even
when provided, different terminologies were used. In
contrast, all the trials providing data on concomitant
medication used the World Health Organization Ana-
tomic Therapeutic Chemical (WHO-ATC) system, the
de facto standard for drug coding in clinical trials [24].
We therefore used concomitant medication data to iden-
tify 21 comorbidities in both the trial and community
datasets.
Trials either reported the ATC codes directly or re-
ported preferred terms often along with the drug route.
In the latter case, we used RxNorm (the US drug
metathesaurus) [25], the UK British National Formulary
[21] and manual review to assign ATC codes. Trial con-
comitant medications were defined as any drug started
on or before the randomisation date.
For the community sample, we used the NHS Business
Authority ATC to Read code lookup table (as processed
by the OpenPrescribing project) [26]. For drugs not
found in the lookup table, we manually mapped Read
code-defined drugs to ATC codes. Any drug prescribed
during 2011 was included.
The following comorbidities (detailed in Additional file 4)
were identified based on medication use: cardiovascular
disease, chronic pain, arthritis, affective disorders, acid-
related disorders, asthma/chronic obstructive pulmonary
disease, diabetes mellitus, osteoporosis, thyroid disease,
thromboembolic disease, inflammatory conditions, benign
prostatic hyperplasia, gout, glaucoma, urinary incontin-
ence, erectile dysfunction, psychotic disorders, epilepsy,
migraine, parkinsonism and dementia. These drug-based
definitions were developed in consultation with a steering
committee comprising clinicians, epidemiologists and stat-
isticians and were finalised before the analysis of the pri-
mary care data.
For each patient/participant, and within each index
condition, we summed the number of individual comor-
bidities, not including the index condition, to obtain a
comorbidity count.
Statistical analysis
Individual-level participant data were held on the YODA
repository for one trial sponsor, on the CSDR secure
platform for the other trial sponsors and on the SAIL se-
cure platform for the community sample. These plat-
forms only allow export of non-disclosive aggregate-level
data. We could not, therefore, include all individual-level
data in a single model.
Therefore, for each trial, we summed the number of
participants with each comorbidity count and exported
this from each secure environment, along with the age-
sex distribution of participants. For each indication, we
obtained the number of community patients with each
comorbidity count within age-sex-specific strata and dir-
ectly standardised these to a weighted average of the trial
age-sex distributions.
We used simulation to obtain uncertainty intervals.
For single trials and community patients, we sampled
from Dirichlet distributions [27]. For indications with
multiple trials, we fitted a Poisson regression model,
similar to a random effects meta-analysis, to the mean
count. Taking posterior samples from this model, we ap-
plied the probability mass function for the Poisson dis-
tribution to obtain the proportion with comorbidity
counts ranging from 0 to 12. In both cases, we obtained
1000 samples, from which we calculated the following
pre-specified statistics: the ratio of mean counts of con-
ditions, the ratio of the proportion with a count ≥ 2 and
the proportion of community patients with a count
greater than the trial median count. For each statistic,
lower and upper uncertainty intervals were obtained as
the 2.5th and 97.5th rank percentiles.
Data were prepared using Structured-query Language
(SQL) and R (Vienna, Austria). The Dirichlet sampling
was performed using R, and the Poisson model was fit-
ted in Just Another Gibbs Sampler (JAGS - http://
mcmc-jags.sourceforge.net/). Aggregated data and code
required to run these models, along with full model de-
scriptions, are available in Additional file 5. The statis-
tical analysis plan, with version history, is available at
https://github.com/dmcalli2/dynamic_protocols/blob/
master/defining_comorbidities_SAIL.md.
Additionally, we compared data elements obtained
from clinicaltrials.gov for trials where we had access to
IPD and included in our analysis, to other trials for
which no individual-level participant data was obtained
(other trials) using descriptive statistics.
Ethical approval
This project had approval from the University of Glas-
gow, College of Medicine, Veterinary and Life Sciences
ethics committee (200160070). SAIL analyses were ap-
proved by SAIL Information Governance Review Panel
(Project 0830).
Results
Of the 124 trials meeting our inclusion criteria and
made available via the CSDR and YODA repositories,
116 (including 122,969 participants for 22 index condi-
tions) provided concomitant medication data allowing
us to identify comorbidities. We had initially planned to
include trials from the NIH BioLINCC repository, but
found that none of the 8 trials which met our eligibility
criteria provided sufficient data on comorbidities to be
included in the analysis (Fig. 1). Index conditions are
summarised in Table 1. Additional file 6 contains a
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summary of the characteristics of each trial. Additional file 7
shows summary statistics of the community sample for
each index condition. Trials included in this analysis and
trials which met our eligibility criteria but were not in-
cluded (either because we did not obtain IPD or because
the data we needed to perform these analyses had been
redacted) were broadly similar in terms of the trial start
dates, study design, excluding conditions and the number
of participants enrolled as well as the clinical indications
and drug classes studied (Additional file 8). However, we
found that trials for inflammatory bowel disease and
rheumatoid arthritis, as well as trials of immunosup-
pressant drugs, were somewhat overrepresented. We
also found that while 11.3% of the IPD trials were
phase 4 trials, 20.9% of non-IPD trials were phase 4,
and that a lower proportion of IPD trials than non-IPD
trials were very large (Additional file 8: Figure S8.1).
For each index condition, most comorbidities were
more common in community patients than in the tri-
als (Fig. 2). In community patients, the seven com-
monest comorbidities, from most to least common,
were chronic pain, cardiovascular disease, arthritis,
affective disorders, acid-related disorders, asthma or
COPD, and diabetes. These conditions were common
across all index conditions, although the ordering var-
ied somewhat. For example, cardiovascular disease
was commoner than chronic pain for both type 2 dia-
betes and COPD. This difference in ordering was evi-
dent for both the community sample and the trials.
Indeed, for most index conditions, those comorbidi-
ties which were commonest in the community were
also commonest for the trials.
For each of the comorbidities assessed, prevalence varied
between trials. Some trials had a prevalence close to that of
Table 1 Trial participants and community patients with each index condition
Index condition Trials Trial participants Community-based sample
Cardiometabolic
Type 2 diabetes mellitus 21 23,750 82,473
Atrial fibrillation 1 18,033 43,330
Hypertension 8 5151 310,691
Thromboembolism 4 9362 9162
Respiratory
Asthma 4 1623 191,160
COPD 7 5256 57,378
Pulmonary fibrosis 2 1063 1465
Pulmonary hypertension 1 406 759
Inflammatory
Axial spondyloarthritis 2 458 1982
Inflammatory bowel disease 12 9241 12,514
Psoriasis 7 7568 52,810
Psoriatic arthritis 3 1331 3523
Rheumatoid arthritis 11 7662 13,809
Systemic lupus erythematosus 2 1693 1033
Musculoskeletal
Osteoarthritis 1 1320 124,521
Osteoporosis 7 14,497 38,212
Neurological
Dementia 7 6253 13,871
Migraine 5 3069 19,562
Parkinson’s disease 3 1368 4727
Restless legs syndrome 2 676 11,480
Urological
Benign prostatic hyperplasia 5 2210 19,906
Erectile dysfunction 1 606 65,736
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the primary care population, while in other trials the preva-
lence was much lower (Fig. 2 and Additional file 9). This
pattern was similar across all index conditions, and for all
comorbidities assessed. No specific comorbidities stood out
as being consistently underrepresented. Conversely, none
was found to be well represented across all trials.
Figure 3 shows the distribution of the comorbidity
counts for trial participants and community-based pa-
tients. For each index condition, the comorbidity distri-
bution for community-based patients lay to the right of
the trial distribution (i.e. more comorbidities in
community patients compared to trial participants). The
community-based counts were standardised to the age-
sex distributions of the trial participants for the relevant
condition. However, the standardisation made little dif-
ference to the estimates (Additional file 10) so only the
age-sex standardised results are presented. For the trial
participants, where there were multiple trials per condi-
tion, the proportions were obtained from the modelled
mean comorbidity counts for each index condition (see
Table 2), under the assumption that the proportion of
trial participants with each comorbidity count follows a
Fig. 2 Scatterplot of the prevalence for each comorbidity for each index condition, for the community-based sample and for clinical trial
participants. Black circles indicate the community-based cohort and red circles trials. The x-axis is sorted according to the prevalence of the
comorbidities in the community-based sample. The sort order was obtained by ranking the comorbidities from commonest to least common for
each index condition, then by taking the median across all index conditions. The individual panels are sorted by the mean comorbidity count for
each index condition, from highest to lowest. Where the index condition was judged to be the same as the comorbid condition, the comorbidity
was not defined, which accounts for apparently missing points on the graph. So, for example, for people in the community sample who had
migraine, the most common comorbidity was chronic pain with the next most common being cardiovascular disease
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Poisson distribution. Where there was only a single trial
for a given condition (e.g. osteoarthritis), raw propor-
tions are shown (see Additional file 5 for details). Co-
morbidity counts varied by index condition. Lower
counts were evident for conditions such as asthma, in-
flammatory bowel disease and psoriasis. Conditions with
higher comorbidity counts were those with a later age of
onset. For most index conditions, the mean comorbidity
counts were between 1.5-fold higher and 3-fold higher
for community-based patients than for trial participants
(Table 2).
Nonetheless, in absolute terms, comorbidity was com-
mon in both settings (Table 2). Most community-based
patients had two or more comorbidities (i.e. three or
more conditions overall) and would therefore be consid-
ered to have a high degree of multimorbidity under
many definitions [28]. In trials, a significant proportion
also had two or more comorbidities. This ranged from
10 to 15% for conditions such as asthma and psoriasis to
around 40–60% for conditions with an older age of onset
such as osteoporosis, dementia and pulmonary fibrosis.
On examining individual trials, the mean comorbid-
ity count was the same or higher in the community
than for every trial (Fig. 4). Nonetheless, there was
considerable variation, even within the same index
conditions. For some trials, the mean comorbidity
counts were almost the same as in the community;
for others, there was more than a twofold difference.
In additional analyses, to explore this variation, we
plotted the mean comorbidity count for each trial
against trial-level characteristics such as the start date,
phase, sponsor and total number of excluding condi-
tions within the eligibility criteria, without observing
any associations (Additional file 11).
Discussion
We examined comorbidity and multimorbidity using
individual-level participant data from 116 trials (122,969
Fig. 3 Proportion with each comorbidity count in trials and community: stratified by index condition. This plot indicates the proportion of
comorbidity counts for each index condition. The height of the plot indicates the percentage of participants/patients with a particular count for
each index condition. For community-based patients, the proportion of patients with each comorbidity count has been standardised to the trial
populations; this was done by applying age-sex-specific proportions to the age-sex distributions of the trial participants. For the trial participants,
where there were multiple trials per condition, the proportion with each comorbidity was obtained from the modelled mean comorbidity counts
for each index condition (see Table 2), under the assumption that the proportion of trial participants with each comorbidity count follows a
Poisson distribution. Where there was only a single trial for a given condition (e.g. osteoarthritis), raw proportions are given. See Additional file 5
for further details of these analyses
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participants) from seven industry sponsors of novel
drug treatments for 22 common index conditions. We
assessed the same comorbidities for the same index condi-
tions from a nationally representative community sample of
2.3 million people. Comorbidity and multimorbidity were
consistently lower in trial populations than in community
patients, but were nonetheless common in both.
Our estimates of comorbidity in the community are
consistent with previous findings: comorbidity was
common, and for some conditions (e.g. COPD and
osteoporosis), it was almost ubiquitous [1, 28]. To
our knowledge, however, ours is the first study to
compare comorbidity and multimorbidity patterns in the
community to those in clinical trial populations by directly
analysing comorbidity counts using individual-level trial
participant data. In so doing, we confirmed that the mean
comorbidity count for trials was approximately half that
observed in the community.
We also found that, although patients with comorbid-
ity or multimorbidity were underrepresented in many
trials, comorbidity and multimorbidity were nonetheless
common. For around half of the index conditions, the
proportion of trial participants with ≥ 2 comorbidities
(i.e. with three conditions and therefore highly multi-
morbid [28]) was above 30%. Given the ubiquity of mul-
timorbidity among patients in the community [1, 28], it
is perhaps unsurprising that comorbidity and multimor-
bidity are so common in industry-funded trials of novel
drugs. However, we do not think that this unexpectedly
high prevalence has previously been noted.
This finding is important because of current uncer-
tainty as to the treatment of people with multimor-
bidity. Guidelines on the treatment of multimorbidity
express reservations about the applicability of trial
evidence to people with multimorbidity [29]. More-
over, in clinical practice, people with comorbidity
(who, by definition, have multimorbidity) are less
likely to receive certain drug treatments recom-
mended across a range of disease-specific guidelines
[2–5]. Our findings that comorbidity and multimor-
bidity are underrepresented in clinical trials would
support a cautious approach by guideline developers
to the routine extrapolation of evidence. However, the
finding that comorbidity and multimorbidity are
Table 2 Comorbidity counts in trial participants and in the community, ordered according to the mean comorbidity counts in the
community
Indication Mean comorbidity count % with comorbidity count > 2
Community (standardised
to trials)
Trials Ratio between mean
counts (community:trials)
Community Trials
Pulmonary fibrosis 3.61 (3.49–3.75) 2.17 (1.03–3.92) 1.87 (0.90–3.49) 0.88 (0.86–0.91) 0.61 (0.28–0.90)
Dementia 3.44 (3.38–3.49) 1.56 (1.10–2.18) 2.27 (1.58–3.11) 0.82 (0.81–0.83) 0.46 (0.30–0.64)
Pulmonary hypertension 3.27 (3.01–3.53) 2.09 (1.93–2.26) 1.57 (1.39–1.75) 0.80 (0.75–0.84) 0.58 (0.53–0.63)
Osteoporosis 3.01 (2.99–3.03) 2.07 (1.43–2.95) 1.50 (1.02–2.10) 0.79 (0.79–0.80) 0.60 (0.42–0.79)
Parkinson’s disease 3.00 (2.90–3.10) 1.36 (0.78–2.18) 2.37 (1.37–3.86) 0.75 (0.73–0.77) 0.39 (0.18–0.64)
Type 2 diabetes mellitus 2.95 (2.94–2.96) 0.79 (0.43–1.32) 4.06 (2.23–6.83) 0.78 (0.78–0.78) 0.27 (0.19–0.36)
Restless legs syndrome 2.85 (2.81–2.89) 1.68 (0.83–2.98) 1.89 (0.96–3.42) 0.74 (0.73–0.75) 0.48 (0.20–0.80)
Pulmonary disease, chronic obstructive 2.76 (2.75–2.78) 1.46 (1.00–2.07) 1.96 (1.33–2.78) 0.75 (0.74–0.75) 0.43 (0.26–0.61)
Thromboembolism 2.52 (2.48–2.56) 1.33 (0.80–2.00) 2.00 (1.24–3.13) 0.68 (0.67–0.70) 0.38 (0.19–0.59)
Systemic lupus erythematosus 2.51 (2.35–2.68) 2.30 (1.08–4.12) 1.22 (0.60–2.32) 0.69 (0.65–0.73) 0.63 (0.29–0.92)
Erectile dysfunction 2.44 (2.43–2.45) 1.08 (0.99–1.17) 2.27 (2.08–2.47) 0.69 (0.69–0.69) 0.32 (0.29–0.36)
Benign prostatic hyperplasia 2.37 (2.34–2.40) 1.11 (0.70–1.69) 2.24 (1.40–3.36) 0.66 (0.66–0.67) 0.30 (0.16–0.50)
Migraine 2.33 (2.31–2.35) 0.98 (0.63–1.42) 2.50 (1.65–3.73) 0.70 (0.69–0.71) 0.26 (0.13–0.42)
Atrial fibrillation 2.22 (2.20–2.23) 1.08 (1.07–1.10) 2.05 (2.01–2.08) 0.63 (0.63–0.64) 0.29 (0.29–0.30)
Osteoarthritis 2.14 (2.13–2.15) 1.79 (1.72–1.86) 1.20 (1.15–1.24) 0.61 (0.61–0.61) 0.54 (0.51–0.56)
Rheumatoid arthritis 2.07 (2.03–2.10) 1.14 (0.87–1.51) 1.84 (1.37–2.39) 0.59 (0.58–0.60) 0.32 (0.22–0.44)
Hypertension 1.91 (1.90–1.91) 0.50 (0.36–0.69) 3.88 (2.76–5.28) 0.54 (0.54–0.54) 0.09 (0.05–0.15)
Psoriatic arthropathy 1.84 (1.78–1.89) 0.67 (0.38–1.09) 2.96 (1.71–4.88) 0.51 (0.50–0.53) 0.15 (0.06–0.30)
Asthma 1.81 (1.81–1.82) 0.58 (0.35–0.92) 3.32 (1.97–5.24) 0.51 (0.50–0.51) 0.12 (0.05–0.23)
Inflammatory bowel disease 1.55 (1.52–1.58) 0.92 (0.68–1.18) 1.73 (1.32–2.28) 0.44 (0.43–0.45) 0.23 (0.15–0.33)
Axial spondyloarthritis 1.42 (1.34–1.50) 0.88 (0.43–1.58) 1.79 (0.90–3.31) 0.40 (0.37–0.43) 0.22 (0.07–0.47)
Psoriasis 1.35 (1.34–1.37) 0.69 (0.48–0.99) 2.02 (1.36–2.80) 0.39 (0.39–0.40) 0.15 (0.08–0.26)
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common in clinical trials is important, because it sug-
gests that trial data could potentially provide an im-
portant resource to allow treatment effects to be
estimated in people with multimorbidity. These
findings have implications for both triallists and for
guideline developers.
The first implication for triallists and guideline devel-
opers relates to making better use of existing evidence.
Fig. 4 Ratio of mean comorbidity counts between community and trials: condition- and trial-level comparisons. Points represent the ratio of
mean count between community patients and trials, and the bars represent 95% credible intervals. Trial estimates are represented by solid circles,
and index-condition-level meta-estimates are represented with empty diamonds. The ratio represents the mean community comorbidity count
for that index condition, divided by the mean trial comorbidity count, i.e. value of 1 indicates no difference in mean comorbidity count, value of
2 indicates the mean comorbidity count is twofold higher in community than in trials, etc. An interactive version of this figure, with links to the
clinicaltrials.gov registration for each trial, is shown in Additional file 12
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One way of doing so is via individual participant-level
data meta-analyses. For this reason, we agree with the
Alltrials initiative, and others, that sharing of IPD from
clinical trials is crucial. Such analyses have helped re-
solve previous controversies about the efficacy of drugs
in different sub-groups, showing, for example, that as-
pirin is similarly efficacious in men and women [30–34].
Similar analyses have the potential to resolve similar
controversies concerning comorbidity and multimorbid-
ity [29, 35], potentially changing clinical practice, either
by providing reassurance that trial findings can be ap-
plied to people with multimorbidity or by providing ro-
bust evidence to the contrary.
However, compared to meta-analysis of published re-
sults, IPD meta-analysis is costly and challenging. If tri-
als are to be widely used to inform clinicians and
guideline developers as to the efficacy of different treat-
ments in the presence of comorbidity or multimorbidity,
trials must publish results according to comorbidity sub-
groups. Doing so will be challenging, however, because
there are multiple different potential patterns of comor-
bidity. This is true even if only a small number of co-
morbid diseases are considered. There are, for example,
64 different possible ways that six conditions can occur
together. Whether important and clinically relevant pat-
terns of comorbidity can be identified from among such
combinations remains an active and unresolved research
question [36]. Nonetheless, we found that those comor-
bidities which were common in the community were
also common in trials. Consequently, if clinically mean-
ingful patterns of comorbidity and multimorbidity can
be identified among people in the community, it may be
possible to identify similar sub-groups among trial
participants.
In the absence of consensus on which patterns of co-
morbidity should be grouped together, we propose that
trials report treatment effects according to the presence/
absence of common comorbidities, as well as by multi-
morbidity counts. Ideally, comorbidities would be de-
fined using medical history data collected in a systematic
and standardised manner across trials. In the absence of
standardised medical histories [9, 37], some insights may
be obtained from existing trials using drug-defined co-
morbidities, particularly where the focus is on conditions
closely associated with particular drug classes (e.g. dia-
betes and glucose-lowering drugs) or on overall mea-
sures of multimorbidity, such as a count.
Despite these challenges, using clinical trial data to es-
timate treatment effects in people with comorbidity or
multimorbidity remains appealing because of limitations
in the alternatives. For example, observational datasets
rich in multimorbidity, such as electronic health records,
are used to estimate treatment effects. However, despite
methodological advances in this use of observational
data, it remains controversial, as unmeasured confound-
ing can result in apparent treatment benefits when none
really exist [9, 38].
The second implication for triallists relates to eligibil-
ity criteria and recruitment. For many indications, there
was little difference in comorbidity counts between some
trials and the community sample, whereas for other tri-
als within the same indication the differences were large.
This suggests that, even for standard industry-funded
phase 3/4 trials, increasing the recruitment of comorbid
participants is feasible. There is therefore potential for
future trials to become more representative in terms of
multimorbidity. In exploratory analyses, the differences
in comorbidity between trials for similar indications
were not related to start date, phase, sponsor or total
number of exclusion criteria. Additional work is needed
to identify the selection processes driving inclusion or
exclusion of people with comorbidity so that trials can
be made more representative. In addition, it will be im-
portant for future research to examine how conditions
cluster in people with multimorbidity and whether this
differs between clinical trial participants and people in
the community in order to improve analysis and report-
ing of treatment effects as well as trial design.
The strengths of our study include large numbers and
that the comorbidity definitions and analyses were pre-
specified before making comparisons. However, there
are several limitations. First, the trials collected medical
history data in a variety of incommensurable ways. Con-
sequently, we used concomitant medications to define
comorbidities. This meant that some important condi-
tions that are not treated with specific medications (e.g.
chronic kidney disease) could not be identified reliably,
whereas some other conditions which share treatments
(e.g. asthma and COPD) had to be combined into
broader categories. The use of some medications was so
heterogenous as to preclude meaningful categorisation,
and we did not attempt to use such drugs in any defin-
ition (for example, since amitriptyline is widely used in
the treatment of chronic pain [39], we did not include it
in our definition of affective disorders). Despite these
limitations, some conditions are well defined by medica-
tions, and importantly, the same definitions were applied
across trial and community data. Our community sam-
ple was taken from Wales because, while being broadly
similar to the rest of the UK, it provides access to elec-
tronic medical records from a large and representative
sample covering 70% of the population [40]. The Welsh
population is broadly similar to the UK population in
demography, and the findings are likely to be applicable
to other high-income countries, but do require replica-
tion in other contexts. In order to facilitate this, we pro-
vide standard comorbidity definitions as well as data on
the distribution of comorbidity counts, age and sex at
Hanlon et al. BMC Medicine          (2019) 17:201 Page 10 of 12
the level of individual trials. A further limitation is that
the included trials were not a random sample of all trials
for these index conditions. Not all sponsors share trial
data. Those who do share data do not make all trials
available. Differences between trials that do or do not
provide IPD may be a potential source of bias [41]. As
such, we believe that the sharing of data by trial
sponsors is to be encouraged, so as to minimise bias
arising from the availability of a limited set of trials.
Nonetheless, the included trials were similar to a wider
body of registered trials across a range of characteristics
(Additional file 8).
Conclusion
Clinical trial populations have a lower prevalence of comor-
bidity and multimorbidity than unselected community pop-
ulations. Clinicians should exercise caution when applying
disease-specific evidence and guidelines to people with co-
morbidity or multimorbidity. Nonetheless, comorbidity and
multimorbidity are common in clinical trials. Given the
limitations of observational data for estimating treatment
effects, this suggests that standard industry-funded clinical
trials are an underused resource for estimating treatment
effects in multimorbidity. We would recommend that fu-
ture disease-specific guidelines need to incorporate infor-
mation concerning likely treatment effects in the context of
the specific index condition and comorbidity or multimor-
bidity. To enable guideline developers to do so, triallists
should at least report the prevalence of multimorbidity and
a range of comorbidities among trial participants and
should consider reporting treatment effect estimates strati-
fied by comorbidity and/or multimorbidity. More general
multimorbidity guidelines could also usefully include infor-
mation in relation to this within any future guideline to
permit more specific guidance for clinicians dealing with
people with multimorbidity.
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